REPL Replimune Group, Inc. Net earnings per share growth this year

REPL (Replimune Group, Inc.) - company brandmark

Replimune Group, Inc. (REPL) maintains a strong R&D team through generous stock options, preventing talent attrition. The shift in earnings per share compared to last year illustrates the business scaling dynamics, where 31.60 serves as the current metric level. The diversity of RP1 platform tests in partnership with pharma behemoths minimizes regulatory risks, while strict adherence to temperature controls during the delivery of viral drugs ensures research stability.

Replimune (REPL): Net earnings per share growth this year from 07/04/2022 to 11/12/2026

Analytical breakdowns and data insights for company Replimune Group, Inc. (REPL)

- current quotes and average value forecast:
Market Chart Replimune Group Inc|REPL - Price Target Chart
- market capitalization data:
Market Valuation Replimune Inc.|REPL - Total Company Value
- company book value details:
Accounting Value per Share Replimune|REPL - Company Net Assets|Market Capitalization to Book Value Ratio replimune.com|REPL - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Ratio Replimune Group, Inc.|REPL - Long-Term Debt to Equity|Current Liabilities to Capital replimune.com|REPL - Company Total Debt|Debt to Net Assets Replimune Inc.|REPL - Company Long-Term Liabilities|Amount of Current Liabilities Replimune|Intermediate Coverage Ratio replimune.com
- net income and valuation ratios data:
REPL - Net Profit|Expected Net Profit Replimune Group, Inc.|REPL - Price to Earnings Ratio|Future Price to Earnings Multiple Replimune Inc.|REPL - PEG Multiple|EV/EBITDA Multiple Replimune Inc.|REPL - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Replimune|REPL - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months replimune.com|REPL - Earnings per share growth in current year|Expected earnings per share trend next year Replimune Group, Inc.
Summary company analysis:REPL (Replimune Group Inc)
Brand item of Replimune Corp

Replimune Group, Inc. (REPL) is striving for a breakthrough in cancer immunotherapy, yet the high capital intensity of its development creates significant financial risks. The annual growth rate of earnings per share measures the pace of change in net income per share relative to the previous year, allowing for an assessment of cost management efficiency and the resilience of share prices amid the uncertainty of clinical trials.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year Immunocore PLC|Net earnings per share growth this year Janux Corp (JANX)|Earnings per share growth in current year Arcus Biosciences, Inc. (RCUS)|Net earnings per share growth this year zymeworks.com ZYME|Tango Therapeutics, Inc. - Net earnings per share growth this year|Earnings growth in current year Iovance Biotherapeutics Inc IOVA|IMTX - Earnings per share growth in current year|XNCR (Xencor Inc.) - Earnings per share growth this year|Compass Therapeutics (CMPX) - Earnings per share growth in current year|Earnings per share growth rate in current year lyell.com (LYEL)|Net earnings per share growth this year IPHA|PYXS - Net earnings per share change in current year|Net earnings per share growth this year CGEN (Compugen Ltd.)|Net earnings per one share growth for the current year IOBT|Earnings growth in current year STRO (Sutro Biopharma, Inc.)|Earnings per share increase in current year INKT|Werewolf - Earnings growth in current year|Earnings per share growth rate in current year Immix Biopharma, Inc.|ALX Oncology (ALXO) - Earnings per share growth in current year|Cue Biopharma Inc. - Earnings per share increase in current year|PDSB (PDS Biotech) - Earnings growth in current year|Earnings growth in current year Sonnet BioTherapeutics Holdings Inc.|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|NextCure Corporation (NXTC) - Earnings per share growth rate in current year|LPTX - Earnings per share growth in current year|Earnings per share increase in current year INTS (Intensity Therapeutics)|SNSE: Earnings growth in current year|Earnings per share growth rate in current year Theriva Biologics Inc (TOVX)|Earnings per share growth in current year Gritstone bio Inc.|Kineta Corp - Earnings per share trend in current year|Earnings per share growth in current year NexImmune, Inc. (NEXI)|Earnings per share growth in current year TSBX (turnstonebio.com)|Earnings growth in current year VCNX (Vaccinex)|Expected net earnings per share growth this year Harpoon Therapeutics Inc (HARP)